Science & Enterprise subscription

Follow us on Twitter

  • A company designing treatments to restore the protective coating on nerve cells damaged by multiple sclerosis is co… https://t.co/wazhT6ZlRp
    about 12 hours ago
  • New post on Science and Enterprise: Genentech, Biotech Partner on Multiple Sclerosis https://t.co/0LVsKWN522 #Science #Business
    about 12 hours ago
  • New contributed post on Science and Enterprise: https://t.co/zBXBbIkYfN Careers Where Banter And Fun Come Into Their Own
    about 17 hours ago
  • A mobile and computer app that alerts older citizens about a class of drugs associated with Alzheimer's disease wil… https://t.co/ayTyKvff5T
    about 1 day ago
  • New post on Science and Enterprise: Trial to Test App Alerting for Dementia-Linked Drugs https://t.co/N6RksAetEY #Science #Business
    about 1 day ago

Please share Science & Enterprise

FDA Proposes Accelerated Medical Device Approval Process

Medical device testing lab

Medical device testing lab (FDA.gov)

23 April 2014. The U.S. Food and Drug Administration proposed yesterday a change in its approval processes for devices that meet unfilled treatment or diagnostic needs of patients with serious medical conditions. The Expedited Access Pre-market Approval Application, says the agency, is designed to speed not only the approval of new medical devices, but also their product development.

FDA also proposed new guidance for its collection of data after initial approval of medical devices to balance reporting requirements with the premarket approval process. The agency is collecting public comments on both proposals for 90 days.

The Expedited Access application aims at speeding up review of pre-market approvals for medical devices that treat or diagnose address unmet needs for life-threatening or debilitating diseases. To invoke this process, a device needs to offer a clinically meaningful advantage over existing technologies and alternatives, and provide a treatment or diagnosis where no approved alternative is available. In addition, applicants need to have a data development plan for the device approved by FDA.

The agency says the process adopts methods from its Innovation Pathway program that brings in regulators at an earlier stage in the product’s development, increases collaboration between regulators and developers, create a better balance between benefit and risk, and make decisions that create momentum to get the device to market. Applicants still need to demonstrate the new device is safe and effective.

“The program allows manufacturers to engage early and often with the agency,” says Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health in an agency statement. “We expect most devices that enter this program will be in the pre-clinical trial phase.”

FDA is also proposing revisions in its procedures for collecting data after initial approval of devices that the agency says complements the Expedited Access program. The proposed procedures, says FDA, outline changes for balancing data collection between pre- and post-market stages in ways that benefit patient access to new devices, while still assuring safety and effectiveness of new devices.

Read more:

*     *     *

 

Comments are closed.